Aspira Pathlab Promoter Jay Arvind Bhanushali Buys 1,599 Shares, Taking Stake to 7.31%

Aspira Pathlab & Diagnostics promoter Jay Arvind Bhanushali acquired 1,599 shares of the company through an open market purchase on November 13, 2026, lifting his stake to 7.31% from 7.29%. ScanX reported the disclosure, which was filed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, in a letter addressed to BSE Limited and copied to the company.

Bhanushali's Open Market Purchase and Filing Details

The filing records Bhanushali's holding at 7,50,796 shares before the transaction and 7,52,395 shares after it. His stake in total capital and in diluted capital moved from 7.29% to 7.31% on both measures. The annexure lists the acquirer as belonging to the promoter or promoter group and names no persons acting in concert with him.

Total share capital was unchanged at ₹10,29,30,000, divided into 1,02,93,000 equity shares of ₹10 each, before and after the acquisition. The filing reports no encumbered shares, with pledge, lien and other encumbrance fields at 0.00 on both sides of the transaction.

The filing's own figures differ on the size of the purchase. The covering letter describes the acquisition as 1599 (0.015%) equity shares, while the annexure reports 0.02% against both total and diluted capital. The annexure's stake figures are shown to two decimal places, so they do not resolve the gap between 0.015% and 0.02%.

Aspira Pathlab's Scale and 2026 Corporate Actions

Aspira Pathlab & Diagnostics is a BSE-listed Indian diagnostic chain operating 18-20+ NABL-accredited centres across Mumbai, Navi Mumbai, Thane, Surat, Nashik and Navsari, offering 1,100+ pathology tests plus sonography and X-ray services, according to akta.pro company records. The same records list 18+ advanced clinical labs, 20+ diagnostic centres and 35 years of experience in the diagnostics industry, with a headcount range of 101-250.

The same records show an open offer launched for fiscal year 2025-2026, described as signaling a potential change in promoter or control structure, and an open offer process initiated during the 2025-2026 fiscal year. They also note multiple senior leadership resignations during 2026.

Resignations and Results Before the Purchase

Aspira Pathlab & Diagnostics reported a standalone net loss of Rs 0.04 crore for the quarter ended June 2026, reversing from a net profit of Rs 0.47 crore in the same period last year, Business Standard reported in August 2026. M/s. Vishal J Bhanushali and Associates resigned as Internal Auditor effective August 13, 2026, citing preoccupation and personal reasons, ScanX reported. Vaibhav Odhekar resigned as Additional Executive Director on July 25, 2026, citing personal reasons, in a disclosure under SEBI LODR Regulation 30, ScanX reported.

What the Filing Leaves Open

The filing does not state whether Bhanushali will make further open market purchases or whether the company's upcoming shareholding pattern filing will reconcile the 0.015% and 0.02% figures.